1. Introduction {#s1}
===============

Chronic pain has been recognized as pain that persists past normal healing time^[@R5]^ and hence lacks the acute warning function of physiological nociception.^[@R35]^ Usually pain is regarded as chronic when it lasts or recurs for more than 3 to 6 months.^[@R29]^ Chronic pain is a frequent condition, affecting an estimated 20% of people worldwide^[@R6],[@R13],[@R14],[@R18]^ and accounting for 15% to 20% of physician visits.^[@R25],[@R28]^ Chronic pain should receive greater attention as a global health priority because adequate pain treatment is a human right, and it is the duty of any health care system to provide it.^[@R4],[@R13]^

The current version of the *International Classification of Diseases* (*ICD*) of the World Health Organization (WHO) includes some diagnostic codes for chronic pain conditions, but these diagnoses do not reflect the actual epidemiology of chronic pain, nor are they categorized in a systematic manner. The *ICD* is the preeminent tool for coding diagnoses and documenting investigations or therapeutic measures within the health care systems of many countries. In addition, *ICD* codes are commonly used to report target diseases and comorbidities of participants in clinical research. Consequently, the current lack of adequate coding in the *ICD* makes the acquisition of accurate epidemiological data related to chronic pain difficult, prevents adequate billing for health care expenses related to pain treatment, and hinders the development and implementation of new therapies.^[@R10],[@R11],[@R16],[@R23],[@R27],[@R31],[@R37]^

Responding to these shortcomings, the International Association for the Study of Pain (IASP) contacted the WHO and established a Task Force for the Classification of Chronic Pain. The IASP Task Force, which comprises pain experts from across the globe,^[@R19]^ has developed a new and pragmatic classification of chronic pain for the upcoming 11th revision of the *ICD*. The goal is to create a classification system that is applicable in primary care and in clinical settings for specialized pain management.

A major challenge in this process was finding a rational principle of classification that suits the different types of chronic pain and fits into the general *ICD-11* framework. Pain categories are variably defined based on the perceived location (headache), etiology (cancer pain), or the primarily affected anatomical system (neuropathic pain). Some diagnoses of pain defy these classification principles (fibromyalgia).

This problem is not unique to the classification of pain, but exists throughout the *ICD*. The IASP Task Force decided to give first priority to pain etiology, followed by underlying pathophysiological mechanisms, and finally the body site. Developing this multilayered classification was greatly facilitated by a novel principle of assigning diagnostic codes in *ICD-11*, termed "multiple parenting." Multiple parenting allows the same diagnosis to be subsumed under more than 1 category (for a glossary of ICD terms refer to Table [1](#T1){ref-type="table"}). Each diagnosis retains 1 category as primary parent, but is cross-referenced to other categories that function as secondary parents.

###### 

Glossary of *ICD-11* terms.
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The new *ICD* category for "Chronic Pain" comprises the most common clinically relevant disorders. These disorders were divided into 7 groups (Fig. [1](#F1){ref-type="fig"}): (1) chronic primary pain, (2) chronic cancer pain, (3) chronic posttraumatic and postsurgical pain, (4) chronic neuropathic pain, (5) chronic headache and orofacial pain, (6) chronic visceral pain, and (7) chronic musculoskeletal pain. Experts assigned to each group are responsible for the definition of diagnostic criteria and the selection of the diagnoses to be included under these subcategories of chronic pain. Thanks to Bedirhan Üstün and Robert Jakob of the WHO, these pain diagnoses are now integrated in the beta version of *ICD-11* (<http://id.who.int/icd/entity/1581976053>). The Task Force is generating content models for single entities to describe their clinical characteristics. After peer review overseen by the WHO Steering Committee,^[@R39]^ the classification of chronic pain will be voted into action by the World Health Assembly in 2017.

![Organizational chart of Task Force, IASP, and WHO interactions. The IASP Task Force was created by the IASP council and its scope defined in direct consultation of the chairs (R.D.T. and W.R.) with WHO representatives in 2012. The Task Force reports to the IASP Council on an annual basis.](jop-156-1003-g002){#F1}

2. Classification of chronic pain {#s2}
=================================

Chronic pain was defined as persistent or recurrent pain lasting longer than 3 months. This definition according to pain duration has the advantage that it is clear and operationalized.

Optional specifiers for each diagnosis record evidence of psychosocial factors and the severity of the pain. Pain severity can be graded based on pain intensity, pain-related distress, and functional impairment.

2.1. Chronic primary pain {#s2-1}
-------------------------

Chronic primary pain is pain in 1 or more anatomic regions that persists or recurs for longer than 3 months and is associated with significant emotional distress or significant functional disability (interference with activities of daily life and participation in social roles) and that cannot be better explained by another chronic pain condition. This is a new phenomenological definition, created because the etiology is unknown for many forms of chronic pain. Common conditions such as, eg, back pain that is neither identified as musculoskeletal or neuropathic pain, chronic widespread pain, fibromyalgia, and irritable bowel syndrome will be found in this section and biological findings contributing to the pain problem may or may not be present. The term "primary pain" was chosen in close liaison with the *ICD-11* revision committee, who felt this was the most widely acceptable term, in particular, from a nonspecialist perspective.

2.2. Chronic cancer pain {#s2-2}
------------------------

Pain is a frequent and debilitating accompaniment of cancer^[@R8]^ that as yet has not been represented in the *ICD*. The Task Force decided to list it as a separate entity because there are specific treatment guidelines.^[@R7],[@R38]^ Chronic cancer pain includes pain caused by the cancer itself (the primary tumor or metastases) and pain that is caused by the cancer treatment (surgical, chemotherapy, radiotherapy, and others). Cancer-related pain will be subdivided based on location into visceral, bony (or musculoskeletal), and somatosensory (neuropathic). It will be described as either continuous (background pain) or intermittent (episodic pain) if associated with physical movement or clinical procedures. The treatment-related pain will be cross-referenced from the chapters on postsurgical pain and neuropathic pain.

2.3. Chronic postsurgical and posttraumatic pain {#s2-3}
------------------------------------------------

Because pain that persists beyond normal healing is frequent after surgery and some types of injuries, the entity of postsurgical and posttraumatic pain was created. This is defined as pain that develops after a surgical procedure or a tissue injury (involving any trauma, including burns) and persists at least 3 months after surgery or tissue trauma^[@R26]^; this is a definition of exclusion, as all other causes of pain (infection, recurring malignancy) as well as pain from a pre-existing pain problem need to be excluded. In view of the different causality, as well as from a medicolegal point of view, a separation between postsurgical pain and pain after all other trauma is regarded as useful. Depending on the type of surgery, chronic postsurgical pain is often neuropathic pain (on average 30% of cases with a range from 6% to 54% and more).^[@R15]^ Pain including such a neuropathic component is usually more severe than nociceptive pain and often affects the quality of life more adversely.^[@R21]^

2.4. Chronic neuropathic pain {#s2-4}
-----------------------------

Chronic neuropathic pain is caused by a lesion or disease of the somatosensory nervous system.^[@R20],[@R22]^ The somatosensory nervous system provides information about the body including skin, musculoskeletal, and visceral organs. Neuropathic pain may be spontaneous or evoked, as an increased response to a painful stimulus (hyperalgesia) or a painful response to a normally nonpainful stimulus (allodynia). The diagnosis of neuropathic pain requires a history of nervous system injury, for example, by a stroke, nerve trauma, or diabetic neuropathy, and a neuroanatomically plausible distribution of the pain.^[@R22]^ For the identification of *definite* neuropathic pain, it is necessary to demonstrate the lesion or disease involving the nervous system, for example, by imaging, biopsy, neurophysiological, or laboratory tests. In addition, negative or positive sensory signs compatible with the innervation territory of the lesioned nervous structure must be present.^[@R36]^ Diagnostic entities within this category will be divided into conditions of peripheral or central neuropathic pain.

2.5. Chronic headache and orofacial pain {#s2-5}
----------------------------------------

The International Headache Society (IHS) has created a headache classification^[@R17]^ that is implemented in full in the chapter on neurology. This classification differentiates between primary (idiopathic), secondary (symptomatic) headache, and orofacial pain including cranial neuralgias. In the section on chronic pain, only chronic headache and chronic orofacial pain will be included. Chronic headache and chronic orofacial pain is defined as headaches or orofacial pains that occur on at least 50% of the days during at least 3 months. For most purposes, patients receive a diagnosis according to the headache phenotypes or orofacial pains that they currently present. The section will list the most frequent chronic headache conditions.

The most common chronic orofacial pains are temporomandibular disorders,^[@R32]^ which have been included in this subchapter of chronic pain. Chronic orofacial pain can be a localized presentation of a primary headache.^[@R2]^ This is common in the trigeminal autonomic cephalalgias, less common in migraines, and rare in tension-type headache. Several chronic orofacial pains such as post-traumatic trigeminal neuropathic pain,^[@R3]^ persistent idiopathic orofacial pain, and burning mouth syndrome are cross-referenced to, eg, primary chronic pain and neuropathic pain. The temporal definition of "chronic" has been extrapolated from that of chronic headaches.^[@R1]^

2.6. Chronic visceral pain {#s2-6}
--------------------------

Chronic visceral pain is persistent or recurrent pain that originates from the internal organs of the head and neck region and the thoracic, abdominal, and pelvic cavities.^[@R24],[@R33],[@R34]^ The pain is usually perceived in the somatic tissues of the body wall (skin, subcutis, muscle) in areas that receive the same sensory innervation as the internal organ at the origin of the symptom (referred visceral pain).^[@R12]^ In these areas, secondary hyperalgesia (increased sensitivity to painful stimuli in areas other than the primary site of the nociceptive input) often occurs^[@R30]^; the intensity of the symptom may bear no relationship with the extent of the internal damage or noxious visceral stimulation.^[@R9]^ The section on visceral pain will be subdivided according to the major underlying mechanisms, ie, persistent inflammation, vascular mechanisms (ischemia, thrombosis), obstruction and distension, traction and compression, combined mechanisms (eg, obstruction and inflammation concurrently), and referral from other locations. Pain due to cancer will be cross-referenced to the chapter chronic cancer pain and pain due to functional or unexplained mechanisms to chronic primary pain.

2.7. Chronic musculoskeletal pain {#s2-7}
---------------------------------

Chronic musculoskeletal pain is defined as persistent or recurrent pain that arises as part of a disease process directly affecting bone(s), joint(s), muscle(s), or related soft tissue(s). According to the constraints of the approach as described in the Introduction, this category is therefore limited to *nociceptive* pain and does not include pain that may be perceived in musculoskeletal tissues but does not arise therefrom, such as the pain of compression neuropathy or somatic referred pain. The entities subsumed in this approach include those characterized by persistent inflammation of infectious, autoimmune or metabolic etiology, such as rheumatoid arthritis, and by structural changes affecting bones, joints, tendons, or muscles, such as symptomatic osteoarthrosis. Musculoskeletal pain of neuropathic origin will be cross-referenced to neuropathic pain. Well-described apparent musculoskeletal conditions for which the causes are incompletely understood, such as nonspecific back pain or chronic widespread pain, will be included in the section on chronic primary pain.

3. Outlook {#s3}
==========

Irrespective of its etiology, chronic pain is a major source of suffering and requires special treatment and care. Our proposal may not represent a perfect solution for the classification of all manifestations of chronic pain. However, it does represent the first systematic approach to implementing a classification of chronic pain in the *ICD*. It is based on international expertise and agreement, and consistent with the requirements of the *ICD* regarding the structure and format of content models. The 7 major categories of chronic pain were identified after considerable research and discussion. They represent a compromise between comprehensiveness and practical applicability of the classification system. Several clinically important conditions that were neglected in former *ICD* revisions will now be mentioned, eg, chronic cancer pain or chronic neuropathic pain. Etiological factors, pain intensity, and disability related to pain will be reflected. With the introduction of chronic primary pain as a new diagnostic entity, the classification recognizes conditions that affect a broad group of patients with pain and would be neglected in etiologically defined categories. We hope that this classification strengthens the representation of chronic pain conditions in clinical practice and research and welcome comments to improve it further.
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Chronic pain (persistent or recurrent pain lasting longer than 3 months)1. Chronic primary pain1.1. Widespread chronic primary pain (including fibromyalgia syndrome)1.2. Localized chronic primary pain (including nonspecific back pain, chronic pelvic pain)1.x. Other chronic primary pain1.z. Chronic primary pain not otherwise specified2. Chronic cancer pain2.1. Chronic pain due to cancer and metastases2.2. Chronic chemotherapy-induced pain (primary parent: chronic neuropathic pain)2.3. Chronic pain due to cancer surgery (primary parent: chronic postsurgical and posttraumatic pain)2.4. Chronic pain due to radiotherapy2.x. Other chronic pain related to cancer2.z. Chronic cancer pain not otherwise specified3. Chronic postsurgical and posttraumatic pain3.1. Chronic postsurgical pain3.2. Chronic posttraumatic pain3.x. Other chronic postsurgical and posttraumatic pain3.z. Chronic postsurgical and posttraumatic pain not otherwise specified4. Chronic neuropathic pain4.1. Peripheral neuropathic pain4.2. Central neuropathic pain4.x. Other neuropathic pain4.z. Neuropathic pain not otherwise specified5. Chronic headache and orofacial pain5.1. Chronic primary headaches\*5.2. Chronic secondary headaches\*5.3. Chronic orofacial pains†5.z. Headache and orofacial pain not otherwise specified\*6. Chronic visceral pain6.1. Chronic visceral pain from persistent inflammation6.2. Chronic visceral pain from vascular mechanisms6.3. Chronic visceral pain from obstruction/distension6.4. Chronic visceral pain from traction/compression6.5. Chronic visceral pain from combined mechanisms6.6. Chronic visceral pain referred from other locations6.7. Chronic visceral pain from cancer (primary parent: chronic cancer pain)6.8. Functional or unexplained chronic visceral pain (primary parent: chronic primary pain)6.x. Other chronic visceral pain6.z. Chronic visceral pain not otherwise specified7. Chronic musculoskeletal pain7.1. Chronic musculoskeletal pain from persistent inflammation7.2. Chronic musculoskeletal pain from structural osteoarticular changes7.3. Chronic musculoskeletal pain due to disease of the nervous system (All neuropathic pain will be classified under 4. Chronic neuropathic pain. Here, other chronic musculoskeletal pain originating from diseases of the nervous system, eg, spastic pain will be listed.)7.4. Chronic nonspecific musculoskeletal pain (primary parent: chronic primary pain)7.x. Other chronic musculoskeletal pain syndromes7.z. Chronic musculoskeletal pain not otherwise specified\*These disorders have in part been renumbered as compared with the ICHD-3. †\#5.3 is not part of the ICHD-3.
